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Sorin V. Pislaru, MD, PHD,* Yan Topilsky, MD,* Maurice Enriquez-Sarano, MD*
Rochester, Minnesota
O B J E C T I V E S The aim of the study is to clarify the clinical role of Doppler-echocardiographic
parameters of left ventricular diastolic dysfunction (LVDD) as determinants of pulmonary hypertension
in patients experiencing left ventricular systolic dysfunction (LVSD) with and without the presence of
functional mitral valve regurgitation (FMR).
B A C KG ROUND Pulmonary hypertension (pulmonary venous or mixed pulmonary venous-arterial
hypertension) complicating LVSD is associated with poor outcomes beyond that of LVSD alone. The view
of the contribution of LVDD as a determinant of pulmonary hypertension is controversial and not well
deﬁned as a tool in clinical practice.
METHOD S Data from patients with LVEF 40% undergoing Doppler-echocardiography evaluations
during the period from August 2001 to December 2004 were analyzed. Pulmonary systolic pressure (PSP),
parameters of diastolic function (mitral valve [MV] transmitral ﬂow velocity [E]/mitral annular diastolic velocity
[e=] ratio, MV deceleration time [DT]), quantitated effective regurgitant oriﬁce area (EROA) of FMR, and clinical
characteristics were evaluated. Pulmonary hypertension was deﬁned as an estimated PSP 45 mm Hg.
R E S U L T S Criteria were met in 1,541 patients; one-third (n  533) demonstrating PSP 45 mm Hg
(58 10 mm Hg, range 45 to 102 mm Hg). Patients with pulmonary hypertension were older with higher
E/e= ratio, EROA, and lower DT and LVEF. In multivariate analysis, pulmonary hypertension was
independently predicted not only by severity of FMR (EROA 20 mm2, odds ratio: 3.8, p  0.001) but
also by parameters of LVDD (E/e= ratio 15, odds ratio: 3.31, p  0.001; DT 150 ms, odds ratio: 3.8,
p  0.001). Receiver-operating characteristics curve analysis showed that EROA, E/e= ratio, and DT provided
signiﬁcant incremental value in predicting pulmonary hypertension (c-statistic 0.830, p  0.001).
CONC L U S I O N S Patients with LVSD commonly have secondary pulmonary hypertension, which is largely
determined by the severity of LVDD even with adjustment for FMR and low LVEF. Thus, measures of LVDD in
routine clinical practice where PSP may not be estimated are important physiologic descriptors of hemodynamic
status and are cumulatively linked in the prediction of pulmonary hypertension. (J Am Coll Cardiol Img 2011;4:
946–54) © 2011 by the American College of Cardiology Foundation
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947eft ventricular systolic dysfunction (LVSD) is a
major factor in the development of symptomatic
congestive heart failure. However, an important
landmark in the progression from uncompli-
ated left ventricular (LV) dysfunction to congestive
eart failure is the development of pulmonary venous
r mixed pulmonary venous/arterial pulmonary
See page 955
hypertension (PH). In clinical series, the frequency
of PH is variable, but its development is associated
with an augmented mortality/morbidity beyond
that of LV dysfunction alone (1–4). Therefore,
defining the causes of PH and the clinical markers
associated with PH carries significant implications
for patient management. In that regard, the role of
left ventricular diastolic dysfunction (LVDD) re-
mains to be clarified.
Doppler echocardiography (D-E) is an essential
tool in the assessment of patients with LV dysfunc-
tion, not only because it allows noninvasive quan-
titation of severity, pulmonary pressures, and func-
tional mitral regurgitation (FMR), but also provides
indirect measures of diastolic function. In previous
studies, these measures were important indepen-
dent determinants of filling pressures in the context
of LVSD (5–7). Particular emphasis has been
placed on the ratio of transmitral flow to mitral
annular diastolic velocities (E/e= ratio) (8), which is
easily measured and, in validation studies, found to
correlate with catheter-measured filling pressures,
and thus serve as a core measure of ventricular
diastolic function (6,7). However, early diastolic
filling flow velocity, which is central to E/e= calcu-
lation, is affected by the severity of FMR (9), which
is commonly associated with LV dysfunction (10).
The value of Doppler-derived indirect measures of
LV diastolic function in estimating LV filling
pressures has been questioned (11). Hence, in
routine clinical practice, the value of basic Doppler-
derived variables of diastolic function in patients
with LVSD, particularly the E/e= ratio, remains
controversial.
Some salient issues in this context remain to be
addressed. First, FMR is an important contributor
to hemodynamic alterations in LVSD (5,12,13),
and its interaction with measures of LVDD, par-
ticularly E/e= ratio, in relation to the development
of PH, is poorly understood (14). Second, the links
between E/e= ratio and PH accounting for FMR
and other LVDD measures in LVSD have not been
evaluated in a large series providing ample statisticalpower. Third, the practical value of these indices,
particularly E/e= ratio, in routine clinical practice is
unclear. Therefore, in our clinical echocardiography
practice in which quantification of LV systolic
function, pulmonary systolic pressure (PSP), FMR,
and LV diastolic function is commonly obtained,
we examined the clinical merit of these physiologic
contributors to the presence and prediction of PH
in patients with LVSD.
M E T H O D S
A retrospective analysis was conducted in
a cohort of patients with LV systolic heart
failure (HF) of ischemic and nonischemic
etiologies and a quantitative measure of
PSP who were evaluated at the Mayo
Clinic, Rochester, during the period of
August 1, 2001, to December 31, 2004.
All patients underwent clinical D-E eval-
uation and were included in this analysis if
the following criteria were met: 1) age
18 years; 2) presence of LVSD defined
by a left ventricular ejection fraction
(LVEF) 40%; 3) PSP measurable by
D-E using tricuspid regurgitation velocity;
4) normal right ventricular systolic func-
tion; 5) measurable diastolic LV function
by assessment of mitral valve (MV) E/e=
ratio and MV deceleration time (MV
DT); and 6) quantitative assessment of
FMR. Exclusion criteria were as follows:
1) atrial fibrillation; 2) organic mitral,
tricuspid, or aortic valvular disease or sta-
tus post any valve replacement/repair; 3)
infiltrative, constrictive, or hypertrophic
cardiomyopathy; 4) myocardial infarction
within 6 months of index D-E; 5) chronic
obstructive pulmonary disease or sleep ap-
nea; 6) congenital heart disease; 7)
tachycardia-related dysrhythmia with heart
rate persistently 100 beats per min; 8) pri-
ary pulmonary arterial hypertension or pulmonary
hromboembolic disease; 9) serum creatinine 2.0
g/dl, 10) history of chest radiation therapy; 11)
ollagen vascular diseases; 12) status after cardiac or
ung transplantation. The study was approved by
he Mayo Foundation Institutional Research Re-
iew Board and included only those patients who
rovided informed consent as required by Minne-
ota Statute 144.335/CRF 21 (Part 50).
Doppler echocardiography. A clinical, comprehen-
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948formed in all patients (15,16), and the original
clinical measurements were used for analysis with-
out remeasurement. LV size and function were
measured according to American Society of Echo-
cardiography recommendations (17). Continuous
wave Doppler was used to assess maximal tricuspid
regurgitation flow velocity to estimate the systolic
pressure gradient between the right ventricle and
right atrium. Right ventricular systolic pressure was
then calculated by adding an estimated right atrial
pressure (18,19). For the purposes of analysis, this
derived pressure was considered to be identical to
PSP after demonstrating the absence of any organic
abnormality of the pulmonary or tricuspid valves.
PH was defined as PSP 45 mm Hg based upon
reported cut-point assessments (4,20). The FMR
was quantified by D-E or by proximal isovelocity
surface area (PISA) methodology using measure-
ments of mitral and aortic stroke volumes and also
quantitative 2-dimensional echocardiography using
measurements of LV volume and stroke volume.
That allowed calculation of the effective mitral
regurgitant orifice area (EROA), and in patients
with no or trace mitral regurgitation by color flow
imaging, the EROA was considered to be zero.
Early transmitral flow velocity (E) and early dia-
stolic mitral annular velocity (e=) were measured
with D-E in the apical 4-chamber view to provide
an estimate of LV diastolic function and pulmonary
pressure (21). The ratio of peak E to peak e= was
calculated (mitral E/e= ratio) from the average of at
least 3 cardiac cycles. The deceleration time of the
E-wave was also measured. Left atrial volume was
calculated using the biplane area length method at
end systole (22). Using pulse wave D-E, the cardiac
index was calculated as the product of aortic stroke
volume and heart rate adjusted for body surface
area.
Statistical analyses. Data are presented as mean 
D or median with 25th and 75th percentiles for
ontinuous data, and as number and percentage for
ategorical data. Two-sample t tests were used to
ompare continuous variables, and signed-rank
nalysis was used to compare medians of values with
onparametric distributions, with statistical differ-
nce accepted for p  0.05. Multiple linear regres-
ion analysis was used to assess associations among
ontinuous clinical and 2-dimensional D-E vari-
bles with PSP. Logistic regression analysis was
erformed using all the independent variables to
ssess their relative contribution (odds ratio [OR])
o the development of PSP 45 mm Hg. The
ncremental value of each clinical and D-E variablen predicting the development of PSP 45 mm Hg
as assessed in terms of the construction of
eceiver-operating characteristic (ROC) curves.
he c-statistic (area under the ROC curve), as a
easure of risk discrimination for PH, was calcu-
ated after the addition of each variable to the base
odel. The significance of the incremental
-statistic value was then determined. The Charl-
on index summating the patient’s individual co-
orbidities including specific heart failure-related
orbidity was calculated to aid in the characteriza-
ion of the study cohort (23). Analyses were done
sing SAS software version 9 (SAS Institute, Cary,
orth Carolina) or S-plus version 7 (Insightful
orp., Durham, North Carolina).
R E S U L T S
Clinical and D-E characteristics. Patient demographic
and clinical characteristics are shown in Table 1.
Whereas a large number of patients met the initial
requirement of LVEF 40% and a reported quan-
titative measure of PSP (n  5,516), a smaller
number met the specific study inclusion/exclusion
criteria and having all the stipulated quantitative
D-E measurements (n 1,541). Pulmonary hyper-
tension defined as a calculated systolic pressure45
mm Hg was used in the analyses of the different
variables as also shown in Table 1. Patients with
elevated PSP were older, more frequently female,
and with lower LVEF and higher Charlson index.
The specific HF component within this comorbid-
ity index was also higher in the patients with
elevated PSP (44% vs. 31%, p  0.001). Patients
were receiving standard oral HF medications, and
there were no differences identified in the distribu-
tion of these medications between patients with and
without elevations in PSP. Median B-type natri-
uretic peptide concentrations were higher in the
patients with elevated PSP (580 vs. 175 pg/ml, p 
0.01). Several Doppler-derived hemodynamic pa-
rameters were also different. Most notable were
parameters of LVDD (E/e= ratio, MV DT).
Approximately one-third of the patient cohort had
PSP 45 mm Hg (n  533) and of these, 190
atients (36%) had PSP 60 mm Hg. An E/e=
atio 15 was present in 78% and MV DT 150
s in 65% of patients with PSP45 mm Hg (both
ut-points reflecting moderate or greater LVDD).
he parameter of moderate or greater FMR,
ROA 20 mm2, was present in 31% of this
subgroup, but nearly one-half (45%) demonstrated
an EROA 10 mm2 consistent with no to trivial
urgit
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949FMR. In the cohort as a whole, 66% of patients had
an EROA 10 mm2.
Associations with PSP are presented as quintiles
of the parameters of diastolic dysfunction—E/e=
ratio (Fig. 1) and MV DT (Fig. 2)—and the
severity of FMR (EROA) (Fig. 3). The LVEF was
less significantly related to an elevated PSP (Fig. 4)
than the Doppler-derived parameters of LVDD. In
multivariate logistic regression analysis, using clin-
ical and quantitative 2-dimensional and Doppler-
derived variables in modeling for PSP45 mm Hg,
LVDD parameters along with age were highly
significant predictors of elevated PSP (Table 2).
The strongest determinants were MV E/e= ratio
15, MV DT 150 ms, and MV EROA 20
mm2. In contrast, LVEF was not an independent
determinant of elevated PSP (OR: 1.25, p 
0.465). The results of the ROC curve analysis for
the determinants of PSP45 mm Hg are shown in
Figure 5. The incremental prognostic value of each
determinant was demonstrated by the addition of
each variable to the model (Table 3). Significant
contributions occurred with the addition of the
parameters of LVDD (MV DT 150 ms and E/e=
Table 1. Clinical, Demographic, and Doppler-Echocardiographic
Overall
(n  1,541)
Age, yrs 68 14
Sex, % male (n) 65.2%
Systemic BP, mm Hg Systolic: 124 22
Diastolic: 70 13
Heart rate, beats per min 73 16
Body mass index, kg/m2 28.1 6.9
Charlson Comorbidity Index 3.02 2.99
Creatinine, mg/dl 1.3 0.49
Potassium, mEq/l 4.3 0.51
BNP, pg/ml 495 539
317 (118–725)
Cardiac index, l/min/m2 2.7 0.7
LVEF, % 30.5 8.3
LA volume, ml 73 29
PSP, mm Hg 40 15
MV EROA, mm2 8 12
EROA 20 mm2 240 (16)
EROA 10–19 mm2 273 (18)
MR volume, ml/beat 32 15
MV E/e= ratio 17 9
E/e= 15 773 (50.2)
MV DT, ms 193 61
Values are mean  SD, median (25th and 75th percentiles), or n (%).
BNP  brain natriuretic peptide; DT  deceleration time; E  transmitral ﬂow
area; LA  left atrial; LVEF  left ventricular ejection fraction; MR  mitral regratio 15) to the model (c-statistic of 0.804, p 0.001) from baseline model of age only (c-statistic
0.605). Adding other markers of elevated filling
pressure (left atrial volume and serum creatinine
concentration) to this model did not significantly
PS
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MV Doppler E/é Ratio
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Figure 1. Box-Plot of Association of Mitral E/e= Ratio by Quintil
Data are presented as medians (line inside the box), interquartile rang
75th percentiles (limits of the box), and 1.5 times IQR above and belo
percentiles (error bars). p  0.001 across quintiles. E/e=  transmitral
racteristics of Patient Cohort
SP <45 mm Hg
(n  1,008)
PSP >45 mm Hg
(n  533)
p
Value
66 14 71 14 0.001
70.2% (705) 56.1% (299) 0.001
124 20/ 125 25/ 0.753
70 13 70 14
71 14 78 14 0.001
28.2 5.8 28.0 8.6 0.338
2.90 2.99 3.25 2.98 0.03
1.2 0.42 1.3 0.59 0.040
4.3 0.50 4.3 0.52 0.160
306 365 763 626 0.01
175 (63–416) 580 (343–972)
2.7 0.6 2.6 0.8 0.015
32.0 7.6 27.8 9.0 0.001
67.1 26.1 84.3 30.7 0.001
31.4 6.4 57.6 10.5 0.001
4.2 8.2 14 14 0.001
77 (7.6) 163 (31)
133 (13.2) 140 (26.3)
29 13 34 16 0.001
13.9 6.9 21.8 10.5 0.001
359 (36) 414 (78) 0.01
209.5 60.2 163 50.9 0.001
city; e=  mitral annular diastolic velocity; EROA  effective regurgitant oriﬁce
ation; MV  mitral valve; PSP  pulmonary systolic pressure.22.6-65
es With PSP
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950add to predictive power (p  0.165 for c-statistic
ncrement to 0.830).
An issue relating to standard clinical practice was
he study requirement that all patients meet pre-
pecified selection criteria, (i.e., that all patients had
o have a quantitative D-E assessment, particularly
or FMR). That was felt to be the best design for
igorous data analysis as a basis for study conclu-
ions. However, many patients in routine clinical
ractice do not have quantitative measurements of
ll the study specified D-E parameters (for various
easons including technical limitations or a focused
valuation based upon the echo referral question).
herefore, many patients have only qualitative as-
MV Deceleration Time (msec)
144 145-170 171-196 197-240 241-498
Association of MV Deceleration Time (ms) by
described for Figure 1. Abbreviations as in Figure 1.
MV Regurgitant Orifice Area (mm2)
-4 5-12 13-18 19-25 26-70
alysis of Association of MV EROA (mm2) by Quintiles, Using
Echocardiography, as Measure of FMR Severity, With PSP
described for Figure 1. EROA  effective regurgitant oriﬁce area;
al valve regurgitation; other abbreviations as in Figure 1.essments of FMR. Thus, we undertook the same
nalysis in the larger initial cohort who met the
asic selection criteria of LVEF 40% and a
easured PSP (n  5,516) and included qualitative
easures of FMR (none-trivial, mild, moderate-
evere, and severe). By this analysis, the parameters
f LVDD (E/e= ratio 15; OR: 2.78, 95% confi-
ence interval [CI]: 2.29 to 3.37, p  0.001) and
V DT150 ms (OR: 3.23, CI: 2.59 to 4.05, p
.001)], FMR [OR: 4.55 [none-trivial vs. severe],
I: 3.30 to 6.30, p  0.001], and age (OR: 5.92,
I: 3.32 to 10.67, p  0.001) remained robust
predictors of PH. Also, LVEF (OR: 1.82, CI: 1.22
to 2.71, p  0.003) was predictive. These findings
upport these parameters of LVDD and FMR
eing effective predictors of PH even when less
tringent patient selection criteria are applied.
D I S C U S S I O N
The findings of this study indicate that in a large
cohort of patients with systolic HF being evaluated
in routine clinical practice, PH is present in approx-
imately one-third of patients. PH is not an isolated
finding and is generally accompanied by left atrial
enlargement and B-type natriuretic peptide eleva-
tion. It is associated with older age (70 years), and
also with several D-E–derived hemodynamic vari-
ables: the parameters of LVDD (E/e= ratio 15
and MV DT150 ms), and the presence and
severity of FMR. In this cohort, these variables are
independent and cumulative predictors of PSP45
mm Hg. Thus, the greater the number of individual
predictors identified extends the probability of PH
being present or at risk of developing when PSP is
not or cannot be measured by D-E techniques.
While these variables reflect a physiologic relation-
ship among LVDD, FMR, and PSP, their clinical
use does not assure the absolute prediction of PH in
the individual patient. Rather, the presence of these
markers of LVDD and FMR in clinical practice
should inform the risk of developing PH and lead to
further assessment and the use of therapeutic options
to prevent the progression to decompensated HF.
The Doppler-derived parameters of LVDD
showed a high frequency in this cohort being
present in 78% of patients with PSP 45 mm Hg
nd were shown to be independent predictors of
H. The severity of FMR with EROA 20 mm2
was also associated with PH independently of all
other variables. This indicator was present, how-
ever, in only one-third of patients with PSP 45PS
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951EROA 10 mm2, indicating the presence of at
least mild-moderate FMR. It also should be noted
that in the patients with PSP45 mm Hg, an E/e=
ratio 15 was present in 36%, whereas MV DT
150 ms and EROA 20 mm2 were present in
nly 12% and 8%, respectively. By inference, that
uggests the presence of elevated left-sided filling
ressure and, therefore, the presence of post-
apillary pulmonary venous hypertension and no
pparent contribution of a pre-capillary pulmonary
rterial hypertension component (20,21,24). It
ould thus appear that, in addition to age, the
egree of LVDD and FMR are the most potent
eterminants of an elevation in PSP in this large
ohort. Extent of LVEF reduction, while shown in
nivariate analysis to be a determinant of PH, was,
owever, not predictive after adjusting for the other
ariables.
Mitral E/e= ratio is accepted as a reliable measure
f ventricular diastolic function and an estimate of
entricular filling pressure (8,14,16,24). Elevated
lling pressures in patients with congestive HF are
riven to a large extent by abnormalities of myo-
ardial relaxation during diastole. The discordance
etween slow relaxation (low e=) of the LV and a
igh E velocity suggests the presence of a high
ressure gradient between the left atrium and LV in
arly diastole. A high E/e= ratio has been considered
good marker of elevated LV filling pressure and
iastolic dysfunction on the basis of this discor-
ance. Thus, E/e= ratio is linked to PH in the
ontext of LVSD, as well as other left-sided heart
isease (25). However, the clinical reliability of
itral E/e= ratio and MV DT as estimators of LV
lling pressure and PH is not unchallenged (11,26).
n a study of 106 patients who underwent echocar-
iography and hemodynamic catheterization evalu-
tions, discordant findings between mitral E/e=
atio and pulmonary capillary wedge pressure were
eported (11). The patients enrolled were being
dmitted for acute decompensated HF and were
eceiving adjustments in their medical therapy and,
herefore, were not in a steady-state condition,
hich might be expected to influence correlations
ith hemodynamic measurements. Also, in that
tudy, no direct measurements of LV end diastolic
ressure were undertaken, pulmonary capillary
edge pressure displayed no association to E/e=
atio, and only a weak negative correlation with MV
T was demonstrated. These findings contrast
ith prior studies that established these D-E pa-
ameters as being reflective of LV filling pressures
16,24) and also with the results of the currenttudy. Our data lend support to a role, in conjunc-
ion with standard-of-care clinical assessment, for
hese Doppler-derived measurements of diastolic
unction in assessing patients with LVSD for high
isk PH. The findings of our study in this respect
re hypothesis generating.
FMR has also been reported to be a marker of
oor outcome in patients with LVSD (14,27,28).
he contribution, however, of FMR to the devel-
pment of PH in patients with chronic LVSD is
ot clear. The severity of FMR would be expected
o influence diastolic function through an effect on
V volume overload. Quantitative D-E assessment
f FMR is, however, subject to loading conditions
f the heart and may, therefore, provide varying
esults. The findings of the current study indicate
hat more severe FMR, as reflected in EROA 20
m2, is an independent determinant of PH, but
may lack sensitivity. Nearly one-half (45%) of the
patients with PSP 45 mm Hg demonstrated an
EROA10 mm2. The contribution of FMR per se
o the development of PH may be through longer-
PS
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LVEF (%)
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5-22
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Figure 4. Box-Plot Analysis of Association of LVEF by Quartiles
Data are presented as described for Figure 1. LVEF  left ventricula
other abbreviation as in Figure 1.
Table 2. Logistic Regression Analysis, Odds Ratio for Risk
of PSP >45 mm Hg
OR 95% CI p Value
Age, yrs 8.39 3.71–19.33 0.001
LVEF, % 1.25 0.68–2.29 0.465
MV EROA 20 mm2 3.72 2.59–5.45 0.001
MV EROA 10–19 mm2 2.13 1.53–3.0 0.001
MV E/e= ratio 15 3.31 2.48–4.43 0.001
MV DT 150 ms 3.85 2.78–5.24 0.00136-40
With PSP
r ejection fraction;CI  conﬁdence interval; OR  odds ratio; other abbreviations as in Table 1.
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Table 1.
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952term consequences such as increases in left atrial
pressure secondary to large regurgitation volume,
and increased LV volume shifting its function to a
steeper portion of the diastolic filling curve. These
may add to the progression of LVDD and may be
the mechanisms whereby patients with reduced
systolic function and FMR experience a poorer
long-term outcome. Our findings confirm the few
prior studies that address FMR and suggest that
FMR imparts hemodynamic consequences and im-
pacts outcome (12,14). Also importantly, the
threshold for these serious complications is lower
than that of organic MV regurgitation (29).
Study limitations. In interpreting these data, several
issues should be considered. Foremost is the retro-
spective design of the study with associated inherit
limitations. Pulmonary pressures were calculated
1-Specificity
0.2 0.4 0.6 0.8 1.0
AUC = 0.830
P< 0.001
Age
Age + LVEF
Age + FMR
Age + LVDD
Age + LVEF, FMR, LVDD + sCr + LA Vol
Analysis
racteristic (ROC) curve analysis of incremental values of clinical
iography–derived variables in the prediction of PSP 45 mm Hg.
age; green line indicates age plus LVEF; gray line indicates age
regurgitation (FMR); dark blue line indicates age plus left ventric-
on (LVDD); and yellow line indicates age plus LVEF, FMR, LVDD,
, and left atrial (LA) volume. AUC  area under the curve; other
ures 1 and 4.
Value of Clinical and Echocardiographic/Doppler Determinants
ROC Curve Analysis
AUC C-Statistic p Value
0.605
0.669 0.001
0 mm2 and EROA 1019 mm2) 0.740 0.001
15 and MVDT 150 ms) 0.804 0.001
LVDD  sCr  LA volume 0.830 0.001
rve; FMR  functional mitral regurgitation; LVDD  left ventricular dystolic
er-operating characteristic; sCr  serum creatinine; other abbreviations as infrom D-E–derived data and no invasive hemody-
namic measurements were obtained for comparison.
The noninvasive methodology, however, has been
well validated and accepted in guideline recommen-
dations as a standard approach to the initial assess-
ment of pulmonary pressure (6–8,24), which is the
measure of interest for this study. Also, while the
measures of LVDD and FMR shown in this study
are independent determinants of PH, there is no-
table individual variability. As such, these measures
should be considered as thresholds for physiologic
determinants of PH more so than absolute markers
for PH in the individual patient. Additionally,
while we were vigorous in excluding patients with
primary lung disease as a basis of elevated PSP, we
cannot be certain that a few such patients were not
included in the analysis; it would not be expected,
however, to significantly impact the findings.
Also, given the absence of a clear consensus for a
specific PSP to define pulmonary venous or mixed
pulmonary venous and arterial hypertension, the
cut-point for our study (PSP 45 mm Hg) could
be considered arbitrary. Therefore, we undertook
additional regression analyses by defining additional
cut-points (PSP50,55, and60 mm Hg). The
results were not significantly changed (EROA 20
mm2 OR: 3.63, 3.00, 2.68, respectively, p  0.001;
/e= 15 OR: 3.76, 5.02, 4.29, respectively, p 
.001; and DT 150 ms OR: 3.46, 3.15, 3.78,
espectively, p  0.001). All were independent
redictors of PH except LVEF, which remained
onpredictive. The c-statistic was not significantly
hanged with the highest cut-point of60 mm Hg
0.839 compared with 0.830 for PSP 45 mm Hg,
 0.424). The overall nature of this study cohort
articularly without a bias for pre-specified cardiac
atheterization reflects more of the routine of stan-
ard clinical practice than would be expected from
linical trial data and, therefore, contributes to a
eneral applicability of these findings.
C O N C L U S I O N S
Pulmonary venous and mixed pulmonary venous/
arterial hypertension are commonly associated with
chronic LV systolic HF. Elevations in PSP appear
to occur independently of the severity of LVEF
reduction but are notably associated with the pres-
ence and severity of LVDD and FMR. FMR most
likely contributes to the development of PH either
directly through its effect on left atrial pressure/
volume or by adding to the longer-term develop-Se
ns
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vi
ty
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Figure 5. ROC Curve
Receiver-operating cha
and Doppler echocard
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plus functional mitral
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serum creatinine (sCR)Table 3. Incremental
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Age  LVEF
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dysfunction; ROC  receivment of diastolic dysfunction through LV dilation
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953and changes in LV filling pressures. While mea-
sures of LVDD and FMR are not always associated
with PH, these indices are strong predictors of
elevated filling pressures and when present, partic-
ularly in the absence of an evaluation of PSP,
should alert the clinician to the prospect of PH
being present. Therefore, these predictors (age,
measures of LVDD, and FMR) can contribute
cumulatively in the determination of the presence
and severity of PH. Prospective studies are neededHeart J 2007;28:2539–50.
1
1
1
1
1
1
1
applications of Doderived variables of LVDD such as MV E/e= ratio
and MV DT (or others) should be a primary focus
for predicting and a therapeutic target for interven-
ing in the course of LV systolic HF to limit the
development of secondary PH and its maladaptive
consequences.
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